Gossamer Bio Faces Lead Plaintiff Deadline as Shareholder Lawsuits Mount

Investors face June 1, 2026 lead plaintiff deadline as lawsuits allege misleading disclosures about Gossamer Bio's failed Phase 3 PROSERA trial, which caused an 80% stock plunge.

The clock is ticking for Gossamer Bio investors who suffered catastrophic losses when the biotech's stock cratered 80% in a single session. With a lead plaintiff deadline of June 1, 2026 fast approaching, multiple US law firms are rallying shareholders to join a class action lawsuit that centers on allegations of misleading disclosures around a pivotal clinical trial.

The Clinical Failure That Sparked the Crisis

At the heart of the litigation is the PROSERA study, which evaluated Gossamer Bio's drug candidate Seralutinib for treating pulmonary arterial hypertension. On February 23, 2026, the company revealed that the Phase 3 trial had missed its primary endpoint — failing to demonstrate a statistically significant improvement in patients' walking distance. The market reacted savagely, with shares plunging from $2.13 to just $0.42.

But the lawsuits allege that the problems were foreseeable. Plaintiffs contend that management misled investors about the study's design, specifically regarding patient recruitment at clinical sites in Latin America. There, an unexpectedly high placebo response among participants made it far more difficult to prove the drug's efficacy through statistical analysis. Critics argue these flaws undermined the entire study's validity from the start.

Regulatory Troubles Compound the Pain

The stock's collapse has triggered a cascade of additional problems. Since late February, Gossamer Bio shares have traded below the $1 threshold, and in April, the Nasdaq formally notified the company that it no longer meets minimum listing requirements. This regulatory pressure adds another layer of uncertainty for shareholders already nursing heavy losses.

The Legal Window for Investors

Investors who purchased Gossamer Bio securities between June 2025 and February 2026 have until June 1, 2026 to petition the court to serve as lead plaintiff. Law firms including Hagens Berman and Rosen Law Firm are currently coordinating applications, seeking to consolidate the various lawsuits that have already been filed.

The outcome of the case will hinge on whether the court determines that the company's communications about the trial's structure and patient recruitment strategy constituted materially misleading information. For Gossamer Bio, the stakes extend well beyond the stock price — the company's credibility in clinical research is now squarely on the line.